Every earnings call for IPCALAB — management tone, guidance, KPIs and promise tracking, quarter by quarter.
IPCALAB · 6 transcripts · Healthcare · latest Q4 FY26IPCA Laboratories Limited has 6 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Consolidated Revenue ₹9,646 cr (+8% YoY); Consolidated EBITDA Margin 20.72%. Consolidated revenue grew 8% to ₹9,646 crores in FY26.
Read full transcript & analysisConsolidated Revenue ₹2,393 cr (+6% YoY); Consolidated EBITDA Margin 22.5%. Consolidated business grew 6.5% to ₹2,393 crores in Q3 FY26.
Read full transcript & analysisStandalone EBITDA Margin 25.46%. Domestic formulation business grew ~8% in Q2 FY26, outpacing IPM growth of 7.8%.
Read full transcript & analysisStandalone EBITDA Margin 23.82%; Standalone Net Profit ₹262 cr (+26% YoY). Standalone net profit up 26% to Rs. 262 crores.
Read full transcript & analysisConsolidated EBITDA ₹1,693 cr (+31% YoY); Consolidated EBITDA Margin 18.94% (+2% YoY). Domestic business grew 12% for FY25, outpacing market growth.
Read full transcript & analysisStandalone EBITDA Margin 24.25% (+6% YoY). Standalone EBITDA margin expanded 573bps to 24.25% in Q3 FY25.
Read full transcript & analysis